Market Overview

Selexis SA Strengthens Cell Line Development Services for Partners with Key Strategic Hires and Investment in State-of-the-Art Laboratory Equipment

Share:

Company's Growth Momentum Continues Following Signing of 100th
Commercial License Agreement

Selexis
SA
today announced it has made key strategic hires, signed its one
hundredth commercial license agreement (CLA) and purchased and installed
$2 million in new laboratory equipment following its acquisition by JSR
Corporation in June 2017. Specifically, the company hired new employees,
to be based in Geneva, the U.S. and Tokyo, in the areas of whole genome
sequencing, global business development, production and operations. The
state-of-the-art laboratory equipment will be housed at the company's
laboratory facility and corporate headquarters, which opened last spring
in the heart of Geneva's biotechnology hub, and will allow Selexis to
serve its growing partner base.

"Getting much-needed medicines into the hands of healthcare providers
quickly and as safely as possible is – and has been – paramount to
Selexis. Our commercial-ready mammalian cell line is helping partners
worldwide achieve their objectives with the highest quality and
predictability," said Igor
Fisch, PhD
, Selexis chief executive officer. "The transition of
Selexis into JSR's Life Sciences division last year strengthened our
ability to help our partners develop increasingly complex
biotherapeutics such as bi-specific proteins, triabodies, DARPins and
novel scaffolds decorated with peptides, to name a few. Additionally,
the integration of Selexis with KBI Biopharma, a subsidiary of JSR,
allows the production of drug substances for clinical trials in as
little as nine months as compared to traditional industry timelines of
16 to 24 months."

Selexis' investment in new equipment and employees is primarily directed
towards the research and development of novel and proprietary
technologies that will enable Selexis to deliver high expressing and
stable research cell banks (RCBs) in eight to nine weeks from
transfection (currently 14 weeks). Furthermore, the investment expands
the Company's capacity to analyze whole genomes using next-generation
sequencing (NGS) methods. Whole-genome sequencing (WGS) provides Selexis
partners new insights into the genome organization of any manufacturing
mammalian cell line. Data from such WGS analysis can be used for safety
intelligence during manufacturing campaigns, and in the near future, for
regulatory submissions.

"We are constantly seeking ways to enhance innovation and, therefore,
increase the speed at which we can deliver high performance cell lines
through our SUREtechnology Platform™– without compromising
stability and safety," said Pierre-Alain Girod, PhD, Selexis chief
scientific officer. "By adding critical talent and enhancing the
equipment in our labs, we're expanding our capabilities and improving
our partners' clinical success."

In May 2017, Selexis opened a
new corporate headquarters and laboratory facility
that tripled its
capacity to meet partner demands. The facility is located in Plan Le
Ouates, a suburb of Geneva, Switzerland. In March 2018, the company
executed its 100th commercial license agreement. The milestone signifies
the value of Selexis' proprietary SUREtechnology Platform, which
facilitates the rapid, stable, and cost-effective production of
virtually any recombinant protein. It also provides seamless integration
of the biologics development continuum, spanning discovery to
commercialization.

About Selexis SA
Selexis SA is a pioneering life sciences
company and a global leader in mammalian (suspension-adapted CHO-K1)
cell line generation, providing unparalleled proprietary technology and
the highly-specialized expertise that is necessary to translate
scientific innovation into life-saving medicines for patients. Selexis'
SUREtechnology Platform™ facilitates the rapid, stable, and
cost-effective production of virtually any recombinant protein and
provides seamless integration of the bioproduction continuum, spanning
discovery to commercialization. With more than 100 partners worldwide,
97 drug products in clinical development and three commercial products
utilizing Selexis-generated cell lines, the Company has a history of
empowering scientists and biopharmaceutical companies around the world
to realize the full potential of their research. More information is
available at www.selexis.com.

FOR MORE INFORMATION
- Web www.selexis.com
-
LinkedIn
www.linkedin.com/company/selexis-sa
-
Twitter
www.twitter.com/SelexisSA
-
Facebook
www.facebook.com/SelexisSA

View Comments and Join the Discussion!